AstraZeneca’s Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the European Union (EU) for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population of adults and adolescents aged 12 years and older weighing at least 40 kg. The full company announcement is available here. The approval by […]

The post AstraZeneca announces Evusheld long-acting antibody combination approved in the EU for the pre-exposure prophylaxis (prevention) of COVID-19 in a broad population appeared first on ThaiPR.NET.

Source: ThaiPR